The pan-BCL-2 inhibitor AT-101 was evaluated in early phase clinical trials for prostate cancer, but off-target gastrointestinal toxicities were dose limiting, and there was no significant anti-cancer activity [104,216,217]. Here, BCL2 is linked to cancer.